Targeted protein degraders Avilar focuses on extracellular protein degraders using ATACs to target disease-causing proteins in circulation, presenting a novel modality that could complement or replace traditional approaches for difficult extracellular targets.

Strategic platform value ATAC platform combines high-affinity ASGPR ligands with modeling of endocytosis and degradation, enabling modular design across the extracellular proteome. This suggests cross-industry collaboration opportunities in partners seeking versatile degradation strategies.

Early-stage pipeline Company is in preclinical/early-stage development with initial proof-of-concept data, indicating a need for translational partnerships, CRO support, or out-licensing discussions to advance lead candidates.

Strategic investments Founded and financed by RA Capital Management with subsequent board additions from Sanofi Ventures, signaling strong investor confidence and potential for co-development or strategic financing discussions and networking.

Market positioning With a small team (11-50 employees) and a distinctive extracellular degradation focus, Avilar may benefit from targeted outreach to pharma companies seeking first-in-class mechanisms, collaboration on target discovery, or supplemental manufacturing and regulatory support as they scale.